HI
TRAW icon

Harbour Investments’s Traws Pharma TRAW Stock Holding History

Harbour Investments’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Buy
+5
New +$7 ﹤0.01% 4755

Other funds holding TRAW

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Harbour Investments's TRAW Position: Q2 2026 in Review

Harbour Investments opened a new position in Traws Pharma (TRAW) in Q2 2026: 5 shares worth $4. The stake represents ﹤0.01% of the portfolio and ranks #4755 among its holdings.

35 funds tracked by Wall St. Rank hold TRAW as of Q2 2026.

  • Harbour Investments held 5 shares of Traws Pharma worth $4 as of Q2 2026.
  • Traws Pharma was a new Harbour Investments position in Q2 2026.
  • Traws Pharma made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4755 holding.
  • 35 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.